Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1714027

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sipavibart
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	23829
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 08:57:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1714032

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Community Nurses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many full-time equivalent district nurses worked in the NHS in England in each financial year since 2009-10.
tabling member constituency	Central Suffolk and North Ipswich
tabling member printed	Dr Dan Poulter
uin	23844
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>NHS England publishes Hospital and Community Health Services workforce statistics for England. These include staff working for hospital trusts and other core organisations, but excludes staff working for other providers such as in primary care, general practice, or social care. This data is drawn from the Electronic Staff Record, the human resources system for the National Health Service. The statistics, including those for district nurses, are available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/monthly-nhs-hospital-and-community-health-service-hchs-workforce-statistics" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/monthly-nhs-hospital-and-community-health-service-hchs-workforce-statistics</a></p><p> </p><p>We know that district nurses will also work outside NHS trusts, for other providers of community services. We do not hold data on the number of district nurses working outside the NHS. The Nursing and Midwifery Council publishes data on the number of nurses with district nursing qualifications on the professional register across the United Kingdom, and is available at the following link:</p><p> </p><p><a href="https://www.nmc.org.uk/about-us/reports-and-accounts/registration-statistics/" target="_blank">https://www.nmc.org.uk/about-us/reports-and-accounts/registration-statistics/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 08:54:56 answering member 4044 label Biography information for Andrew Stephenson
tabling member	3932 label Biography information for Dr Dan Poulter

1714075

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Autism and Learning Disability
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the effectiveness of NHS England’s Dynamic Support Register policy.
tabling member constituency	South Swindon
tabling member printed	Sir Robert Buckland
uin	23859
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>NHS England published updated policy and guidance on Dynamic Support Registers (DSRs) and Care (Education) and Treatment Reviews (C(E)TRs) on 25 January 2023, for implementation from 1 May 2023. The purpose of the updated policy and guidance is to help ensure that people with a learning disability and autistic people get the right support, to stay well in their communities.</p><p>NHS England produced the updated policy and guidance following a process of reviewing the learning since the inception of DSRs and C(E)TRs, including consultation and engagement with people with lived experience. This process included drawing on the findings of the Norfolk Safeguarding Adults Board’s review of the deaths of Joanna, Jon, and Ben at Cawston Park in Norfolk, and the subsequent safe and wellbeing reviews for all people with a learning disability and autistic people in mental health hospitals.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 02/05/2024 14:21:54 answering member 4492 label Biography information for Maria Caulfield
tabling member	4106 label Biography information for Sir Robert Buckland

1714076

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Trastuzumab Deruxtecan
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations she has made to NICE on the availability of Enhertu.
tabling member constituency	Brentford and Isleworth
tabling member printed	Ruth Cadbury
uin	23881
answer	answer is ministerial correction date of answer 02/05/2024 answer text <p>The Department meets regularly with the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including access to medicines. The NICE has recommended Enhertu, also known as trastuzumab deruxtecan and made by Daiichi Sankyo, for use through the Cancer Drugs Fund, for the treatment of HER2-positive metastatic or unresectable breast cancer. It is available to eligible National Health Service patients in England, in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of HER2-low metastatic or unresectable breast cancer. Following negotiations between NHS England and the company, which concluded without a commercial agreement to make it available at a cost-effective price for the NHS, the NICE published final draft guidance on 5 March 2024, that does not recommend it as an option for this indication. The NICE remains open to further discussions with NHS England and the company, and currently expects to publish final guidance on 15 May 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/05/2024 11:47:11 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4389 label Biography information for Ruth Cadbury

1714079

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gabapentin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23890
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.</p><p>The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 09:02:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1714080

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gabapentin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will take steps to ensure that people experiencing acute or chronic side effects from taking gabapentin do not have to wait for a (a) referral and (b) assessment by mental health services.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23891
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>While we have no specific plans to do so, we are committed to expanding and transforming mental health services in England through the NHS Long Term Plan, so that more people, including those experiencing side effects from taking gabapentin, can get the mental health help and support that they need.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 01/05/2024 15:56:56 answering member 4492 label Biography information for Maria Caulfield
tabling member	4471 label Biography information for Rachael Maskell

1714081

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alcoholic Drinks: Children and Young Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking with Cabinet colleagues to help tackle under-age alcohol use.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23892
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Guidance from England’s Chief Medical Officer for healthcare professionals is clear, an alcohol-free childhood is the healthiest and best option. The Department promotes this through online platforms such as the NHS.UK website, and the Talk to FRANK online resource. Local authorities promote these guidelines as part of their public health duties.</p><p>The Department for Education’s statutory guidance, Relationships education, relationships and sex education and health education, became mandatory in September 2020. Through this, education on drugs, alcohol, and tobacco became compulsory at state-funded primary and secondary schools, teaching children and young people how to manage influences and pressures, and keep themselves healthy and safe.</p><p>To deter individuals selling alcohol to a person aged under 18 years old, the maximum fine for the offence of persistently selling alcohol to children was increased from £10,000 to £20,000, under s 147A(8) of the 2003 Licensing Act.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 01/05/2024 12:20:25 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4471 label Biography information for Rachael Maskell

1714094

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the availability of heart valve surgery for (a) women and (b) ethnic minorities.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	23907
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23908 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4571 label Biography information for Gill Furniss

1714095

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heart Diseases: Women
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase awareness of the symptoms of heart valve disease in women.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	23908
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23907 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4571 label Biography information for Gill Furniss

1714123

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Shingles: Warrington
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase uptake of the shingles vaccine by people aged over 65 in Warrington.
tabling member constituency	Warrington South
tabling member printed	Andy Carter
uin	23963
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Joint Committee on Vaccination and Immunisation has recommended that those who are eligible for the shingles vaccine should change, to allow individuals to be protected at an earlier age, particularly those that have a weakened immune system. Based on the evidence, they recognised that there may be more clinical benefit from starting shingles vaccinations at a lower age, with modelling indicating that a greater number of cases of shingles would be prevented with vaccination at 60 years old for immunocompetent individuals, and 50 years old for immunosuppressed individuals. The committee advised that the programme should be implemented in stages, starting with those that are over 50 years old with a weakened immune system and those turning 65 and 70 years old, then eventually moving down to those turning 60 years old. This is a similar pattern to the roll out of the shingles vaccine from 2013. This is why the vaccine offer has been expanded to all those turning 65 and 70 years old and all those over 50 years old with a weakened immune system, from 1 September 2023. The programme began on 1 September 2023 and will run until 31 August 2028, offering the vaccine to people as they turn 65 and 70 years old, until the offer has been made to all those aged 65 to 70 years old. It will then expand to offering the vaccine to all those that are turning 60 and 65 years old, from 1 September 2028.</p><p>The shingles vaccine is available through general practice (GP) surgeries in primary care, and GPs are required to identify and put in place a call or recall arrangement to offer the shingles vaccination to eligible patients. All eligible patients are contacted by their GP surgery to invite them for vaccination. The GP will then follow up with letters or with calls and text messages, to encourage eligible people that have not come forward to take up the offer.</p><p> </p><p>There is a wide range of public facing information to help increase uptake of the shingles vaccine, and to publicise the programme in GP surgeries and online, including display bunting, leaflets, and posters. GPs are also adding messages regarding shingles to their practice websites, prescription counterfoils, and social media banners. Public facing information regarding the shingles vaccination programme includes translations into over 20 different languages including braille, audio, large print, and British Sign Language. Information for healthcare professionals, including GP toolkits for improving uptake of shingles vaccination, has also been produced and published by local immunisation commissioning teams.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 01/05/2024 12:52:34 answering member 4492 label Biography information for Maria Caulfield
tabling member	4791 label Biography information for Andy Carter